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A series of new arylamide derivatives possessing terminal sulfonate or sulfamate moieties was designed
and synthesized. The target compounds were tested for in vitro inhibitory effects against the steroid sul-
fatase (STS) enzyme in a cell-free assay system. The free sulfamate derivative 1j was the most active. It
inhibited the enzymatic activity by 72.0% and 55.7% at 20 lM and 10 lM, respectively. Compound 1j was
further tested for STS inhibition in JEG-3 placental carcinoma cells with high STS enzyme activity. It
inhibited 93.9% of the enzyme activity in JEG-3 placental carcinoma cells at 20 lM with an efficacy near
to that of the well-established drug STX64 as reference. At 10 lM, 1j inhibited 86.1% of the STS activity of
JEG-3. Its IC50 value against the STS enzyme in JEG-3 cells was 0.421 lM. Thus, 1j represents an attractive
new non-steroidal lead for further optimization.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
The steroid sulfatase (STS) enzyme catalyzes the hydrolysis of
inactive sulfate metabolites such as estrone sulfate and dehy-
droepiandrosterone sulfate to the more active estrone and dehy-
droepiandrosterone, respectively. The production of 90% of
androstenediol (Adiol) comes from dehydroepiandrosterone
released through the STS pathway.1 Despite the androgenic struc-
ture of Adiol, it still possesses some estrogenic properties. Adiol is
about 100 times weaker than estradiol,2–5 with lower affinity for
the estrogen receptor.6 However, the Adiol concentration in the
circulation is 100-fold higher than estradiol. This led to speculation
that it might be equipotent to estradiol.7 In addition, the STS path-
way produces a significant amount of estrogen besides that pro-
duced by aromatase, the enzyme which catalyzes the
aromatization of androgen to estrogen. This has been supported
by: (1) STS activity in liver, normal breast tissues, and breast cancer
tissues is million fold higher than aromatase activity;8 (2) estrone
produced from estrone sulfate through the STS pathway is about10-fold higher than that produced from androstenedione through
aromatase action;9 and (3) STS expression is a very essential prog-
nostic factor in human breast carcinoma.10,11 Thus, STS is an attrac-
tive target for the treatment of hormone-dependent breast,12
endometrial,13 prostate cancers, and endometriosis.14
Several articles have recently highlighted different steroidal and
non-steroidal agents capable of inhibiting STS.12,15–21 Estrone 3-O-
sulfamate (EMATE, Fig. 1) is an example of a potent steroidal STS
inhibitors, but when orally tested in vivo it exerted estrogenic side
effects as demonstrated by its ability to increase the uterine weight
in ovariectomized Wistar rats.22 Attention was therefore switched
to non-steroidal STS inhibitors to avoid such effects. The coumarin
sulfamate derivative STX64 (Irosustat, 667 COUMATE, Fig. 1) has
been the most potent and successful STS inhibitor to date. It is cur-
rently being investigated in clinical trials for treatment of estro-
gen-dependent breast cancer, and has been trialed in
endometrial cancer and prostate cancer. STX64 is an irreversible
STS inhibitor due to the presence of the sulfamate moiety that
covalently binds to the enzyme.16 On the other hand, some estrone
sulfonate derivatives have been reported as reversible STS inhibi-
tors because the sulfonate moiety is unable to make a covalent
bond with the enzyme as the sulfamate analogues.23,24
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Figure 1. Structures of Estrone sulfate, EMATE, STX64, and the target compounds
1a–m.
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potential sulfatase inhibitors. In the present study, a series of ary-
lamide derivatives possessing sulfonate or sulfamate moieties was
designed to mimic estrone sulfate and dehydroepiandrosterone
sulfate, the substrates of STS. As illustrated in Figure 1, the two ring
system of the target compounds mimic rings A and D of estrone
sulfate and EMATE with a 2-atom spacer. In another orientation,
it can also mimic the aromatic and the cycloheptane rings of
STX64 with an amide linker as an isostere of the coumarin ester
moiety. Thirteen target compounds were synthesized and evalu-
ated for STS inhibitory effect in a cell-free enzymatic assay. The
most promising compound was further tested for its STS inhibitory
effect in whole JEG-3 placental carcinoma cells that have high STS
enzyme activity. The results and experimental protocols are set out
below.
2. Results and discussion
2.1. Chemistry
The target compounds 1a–m were synthesized via the pathway
illustrated in Scheme 1. 4-Aminophenol (2) was reacted with
cyclohexanecarbonyl chloride (3a) or cyclopentanecarbonyl chlo-
ride (3b) in the presence of anhydrous potassium carbonate to
afford the phenolic intermediates 4a,b. Some precautions were
taken into consideration in this reaction to avoid disubstitution,HO
NH2
+ Cl
O
2 3a,b
i
HO
n
H
N
4a
O
S
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O O
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Scheme 1. Reagents and conditions: (i) anhydrous K2CO3, acetone, 0 C, rt, 4 h; (ii) appr
88% (two steps); (iii) appropriate sulfamoyl chloride derivative, NaH, anhydrous DMF, 0such as the order of addition, rate of addition, dilution with sol-
vent, and stirring while adding the acid chlorides to 4-aminophe-
nol. Interaction of the hydroxyl intermediates 4a,b with the
appropriate sulfonyl chloride derivatives in the presence of triethy-
lamine produced the target sulfonate compounds 1a–i. To obtain
the target sulfamate analogues 1j–m, compounds 4a,b were
reacted with the appropriate sulfamoyl chloride reagents in pres-
ence of anhydrous sodium hydride under N2. The detailed struc-
tures of the target compounds are illustrated in Table 1.
2.2. Biological screening
2.2.1. Cell-free enzyme inhibition testing
All the thirteen target compounds 1a–mwere tested at a single-
dose concentration of 10 lM against the STS enzyme. The inhibi-
tory effects are depicted in Figure 2. The results show that com-
pound 1j is the most active amongst this series of compounds. It
possesses a free sulfamate ‘warhead’ moiety, similar to the lead
compound STX64. Irosustat (STX64) has been reported as an irre-
versible inhibitor of STS. The irreversible inhibitors are usually
stronger than the corresponding reversible inhibitory agents. This
explains the stronger activity of the free sulfamate analogue 1j that
likely irreversibly also inhibits the enzyme similar to STX64, com-
pared to the sulfonate derivatives that were less active.
The free sulfamate compound 1j was significantly more active
than the N-substituted sulfamate derivatives 1k and 1l. This find-
ing complies with earlier data reported for STX64 and its steroidal
counterparts compared with the corresponding substituted sulfa-
mate analogues.16 The substituted sulfamate moieties have been
reported as reversible inhibitors and non-covalent binders relative
to the free sulfamate.25 This can rationalize the stronger activity of
free sulfamate derivatives compared to the substituted sulfamates.
Among the aliphatic sulfonate analogues, the ethanesulfonate
1b was the most active, and the p-tosylate derivative 1e was more
active than the other aromatic sulfonates. Upon investigating the
effect of the cycloalkyl ring size on activity, the cyclohexyl deriva-
tives 1e and 1kwere more active than the corresponding cyclopen-
tyl analogues 1i and 1m. So the bulkier cyclohexyl ring is more
optimal for activity maybe due to stronger hydrophobic interac-
tions and/or steric influence. Any or both of these effects might
enhance the affinity to the enzyme and hence confer a stronger
inhibitory effect.
The most promising compound 1jwas further studied in 5-dose
testing mode at 20, 10, 5, 1, and 0.5 lM concentration in compar-
ison with STX64. The results are illustrated in Figure 3. Compound
1j inhibited the enzyme in a dose-dependent manner. It inhibitedO
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opriate sulfonyl chloride derivative, triethylamine, anhydrous THF, 0 C, rt, 2 h, 80–
C, rt, overnight, 83–90% (two steps).
Table 1
Structures of the target compounds 1a–m
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Compound No. R n
1a Me 2
1b Et 2
1c n-Pr 2
1d Ph 2
1e 4-Me(C6H4) 2
1f 4-tert-Butyl(C6H4) 2
1g 4-F(C6H4) 2
1h 4-CF3(C6H4) 2
1i 4-Me(C6H4) 1
1j NH2 2
1k NHMe 2
1l N(Me)2 2
1m NHMe 1
2764 M. I. El-Gamal et al. / Bioorg. Med. Chem. 24 (2016) 2762–276772.0% of the enzymatic activity at 20 lM concentration. This com-
pound could be a useful template for future lead optimization to
design new STS inhibitors.
2.2.2. Cell-based enzyme inhibition testing
Compound 1j was further tested for STS enzyme inhibition in a
JEG-3 placental carcinoma cell line with over-expressed STS. It was
tested at five different concentrations starting from 20 lM, and
compared with STX64 (1 lM) as a reference standard. Compound
1j could clearly penetrate the cell membrane to enter the cells,
so it is hydrophobic enough to this end. It inhibited the JEG-3
STS in a dose-dependent manner as illustrated in Figure 4. The
inhibition at 20 lM was 93.9%, very close to the result for STX64
result; the enzyme activity was inhibited by 86.1% at a 10 lM con-
centration of 1j.
Compounds 1j and STX64 were further tested in an 8-dose test-
ing mode in order to study the dose-STS response (Fig. 5) and cal-
culate the IC50 values of both compounds. The IC50 values of STX64
and compound 1j against STS activity were 1.7 nM and 0.421 lM,
respectively.
3. Conclusion
In the present study, a new series of sulfonate- or sulfamate-
containing arylamide compounds was designed and synthesized.
All the target compounds were characterized by 1H NMR, 13C
NMR, IR, and LC–MS analyses. They were tested for STS inhibitory
effects against JEG-3 lysate. The free sulfamate compound 1j was
the most active among this series of compounds; it inhibited the
enzyme in a dose-dependent manner and it was much more active
than the sulfonate or N-substituted sulfamate analogues. The
cyclohexyl motif was found more favorable for activity than cyclo-C STX64 1a 1b 1c 1d 1e
0
50
100
%
 S
TS
 in
hi
bi
tio
n
Figure 2. Inhibition percentages expressed by compounds 1a–mpentyl. Compound 1j could penetrate the cell membrane of JEG-3
placental carcinoma cells rich in STS activity to inhibit the enzyme
inside the cells in a dose-dependent manner. It showed very high
and promising STS inhibitory effects against JEG-3 cells, albeit
weaker than Irosustat. Thus, this compound provides a promising
hit for future lead optimization in order to develop perhaps still
more potent and more promising STS enzyme inhibitors. Further
decoration of the two ring systems to this end should be straight-
forward to accomplish.4. Experimental
4.1. General
The target compounds were purified by column chromatogra-
phy using silica gel (0.040–0.063 mm, 230–400 mesh) and techni-
cal grade solvents. IR spectra (KBr discs) were recorded with a
Bruker FT-IR instrument (Bruker Bioscience, Billerica, MA, USA).
1H NMR and 13C NMR spectra were recorded on a Bruker Avance
400 spectrometer using tetramethylsilane as an internal standard.
LC–MS analyses were carried out in positive ion mode by Electro-
spray Ionization (ESI) on (Waters) ACQUITY UPLC triple Quadru-
pole (Xevo TQD) instrument equipped with MassLynx software.
The samples were dissolved in methanol diluted in spray solution
(methanol/water 1:1 v/v 0.1% formic acid) and infused directly in
combined mode with a flow rate of 0.3 mL/min. Melting points
were obtained on a Walden Precision Apparatus Electrothermal
9300 apparatus and are uncorrected. Solvents and liquid reagents
were transferred using hypodermic syringes. All solvents and
reagents were commercially available and used without further
purification.
4.2. Synthesis of N-(4-hydroxyphenyl)cyclohexanecarboxamide
(4a) and N-(4-hydroxyphenyl)cyclopentanecarboxamide (4b)
To a solution of 4-aminophenol (100 mg, 0.916 mmol) in ace-
tone (15 mL), anhydrous K2CO3 (152 mg, 1.1 mmol) was added.
The reaction mixture was stirred at room temperature for
15 min, then cooled to 0 C. A solution of cyclohexanecarbonyl
chloride or cyclopentanecarbonyl chloride (0.833 mmol) in ace-
tone (10 mL) was added dropwise to the reaction mixture at 0 C
with continuous stirring. After complete addition, the reaction
temperature was raised to room temperature, and stirring was
continued for 4 h. The reaction mixture was filtered, and the fil-
tered solid was washed with acetone (2  10 mL). The combined
filtrate and wash were evaporated to dryness. The residue was dis-
solved in ethyl acetate (10 mL) and extracted with dilute HCl. The
organic layer was then washed with saline (2  10 mL), and dried
with anhydrous sodium sulfate. The organic solvent was evapo-
rated under reduced pressure to get the intermediate title com-
pounds. They were used in the next steps without further
purification.1f 1g 1h 1i 1j 1k 1l 1m
at 10 lM concentration against steroid sulfatase enzyme.
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Figure 3. % inhibition exerted by STX64 and compound 1j at different concentrations against cell-free STS enzyme. The results are expressed as mean of triplicate
assay ± SEM.
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Figure 4. (a) % inhibition exerted by STX64 and compound 1j at different concentrations against STS enzyme in JEG-3 placental carcinoma cells. (b) Residual STS enzyme
activity after treatment with STX64 and compound 1j. The results are expressed as mean of a triplicate assay ± SEM.
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Figure 5. % STS enzyme activity in JEG-3 cells upon treatment with different
concentrations of STX64 and compound 1j.
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A solution of compound 4a,b (0.456 mmol) in dry THF (10 mL)
was cooled to 0 C, and triethylamine (0.25 mL, 2.47 mmol) was
added thereto. A solution of the appropriate sulfonyl chloride
(0.90 mmol) in dry THF (3 mL) was added dropwise to the reaction
mixture at the same temperature. The reaction mixture was stirred
at room temperature for 2 h. After reaction completion, the mix-
ture was quenched with ethyl acetate (10 mL) and water (10 mL).
The organic layer was separated, and the aqueous layer was
extracted with ethyl acetate (3  5 mL). The combined organic
layer extract were washed with saline (3  10 mL), and dried over
anhydrous sodium sulfate. The organic solvent was evaporated
under reduced pressure, and the crude residue was purified by col-
umn chromatography (silica gel, appropriate ratio of hexane/ethyl
acetate) to obtain the pure product.
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(1a)
Yield: 87%; mp: 173–6 C; IR (KBr disc, cm1): 3324 (NH), 2931,
2853 (CAH stretching), 1668 (C@O), 1524, 1371 (OSO2); 1H NMR
(400 MHz, CDCl3) d 7.58 (d, 2H, Ar-H, J = 8.0 Hz), 7.43 (s, 1H, NH),
7.21 (d, 2H, Ar-H, J = 8.0), 3.12 (s, 3H, CH3), 2.28–2.20 (m, 1H, cyclo-
hexyl-H), 1.94 (d, 2H, cyclohexyl-H, J = 12.0 Hz), 1.86–1.82 (m, 2H,
cyclohexyl-H), 1.72–1.67 (m, 2H, cyclohexyl-H), 1.58–1.49 (m, 2H,
cyclohexyl-H), 1.29–1.26 (m, 2H, cyclohexyl-H); 13C NMR
(100 MHz, CDCl3) d 174.6 (C@O), 145.0, 137.4, 122.5 (2C), 121.1
(2C) [Ar-C], 46.4, 37.2, 29.6 (2C), 25.6 (2C) [aliph. C]; LC–MS: m/z
298.07 [M+ +1].
4.3.2. 4-(Cyclohexanecarboxamido)phenyl ethanesulfonate (1b)
Yield: 85%; mp: 140–2 C; IR (KBr disc, cm1): 3309 (NH), 2924,
2853 (CAH stretching), 1660 (C@O), 1527, 1349 (OSO2); 1H NMR
(400 MHz, CDCl3) d 7.59 (br s, 1H, NH), 7.57 (d, 2H, Ar-H,
J = 8.0 Hz), 7.19 (d, 2H, Ar-H, J = 12.0 Hz), 3.26 (q, 2H, CH2CH3,
J = 8.0 Hz), 2.28–2.20 (m, 1H, aliph.-H), 1.94–1.91 (m, 3H, cyclo-
hexyl-H), 1.85–1.81 (m, 2H, cyclohexyl-H), 1.71–1.68 (m, 1H,
cyclohexyl-H), 1.52 (t, 3H, CH2CH3, J = 8.0 Hz), 1.28–1.26 (m, 3H);
13C NMR (100 MHz, CDCl3) d 174.7 (C@O), 144.8, 137.3, 122.5
(2C), 121.1 (2C) [Ar-C], 46.4, 44,9, 29.6 (2C), 25.6 (2C), 8.2 [aliph.
C]; LC–MS: m/z 312.24 [M+ +1].
4.3.3. 4-(Cyclohexanecarboxamido)phenyl propane-1-sulfonate
(1c)
Yield: 86%; mp: 150–3 C; IR (KBr disc, cm1): 3313 (NH), 2924,
2853 (CAH stretching), 1661 (C@O), 1528, 1335 (OSO2); 1H NMR
(400 MHz, CDCl3) d 7.59 (br s, 1H, NH), 7.56 (d, 2H, Ar-H,
J = 8.0 Hz), 7.18 (d, 2H, Ar-H, J = 8.0 Hz), 3.22–3.18 (m, 2H, aliph.-
H), 2.28–2.20 (m, 1H), 2.03–2.00 (m, 1H, aliph.-H), 1.98 (d, 1H,
aliph.-H, J = 8.0 Hz), 1.92 (d, 2H, cyclohexyl-H, J = 16.0 Hz), 1.84–
1.77 (m, 2H, cyclohexyl-H), 1.71–1.69 (m, 1H, cyclohexyl-H), 1.58–
1.48 (m, 2H, cyclohexyl-H), 1.27–1.25 (m, 4H, cyclohexyl-H), 1.11
(t, 3H, CH2CH2CH3, J = 8.0 Hz); 13C NMR (100 MHz, CDCl3) d 174.8
(C@O), 144.8, 137.2, 122.5 (2C), 121.1 (2C) [Ar-C], 51.9, 46.3, 29.6
(2C), 25.6 (2C), 17.3, 12.8 [aliph. C]; LC–MS:m/z 326.0 [M+ +1].
4.3.4. 4-(Cyclohexanecarboxamido)phenyl benzenesulfonate
(1d)
Yield: 80%; mp: 156–9 C; IR (KBr disc, cm1): 3319 (NH), 2927,
2854 (CAH stretching), 1665 (C@O), 1519, 1377 (OSO2); 1H NMR
(400 MHz, CDCl3) d 7.81–7.79 (m, 2H, Ar-H), 7.68–7.64 (m, 2H,
Ar-H), 7.53–7.46 (m, 4H, Ar-H), 6.87 (d, 2H, NH, J = 8.0), 2.26–
2.18 (m, 1H, cyclohexyl-H), 1.89 (d, 2H, cyclohexyl-H,
J = 12.0 Hz), 1.80–1.77 (m, 2H, cyclohexyl-H), 1.67 (d, 1H, cyclo-
hexyl-H, J = 8.0 Hz), 1.50 (d, 2H, cyclohexyl-H, J = 12.0 Hz), 1.26–
1.21 (m, 3H, cyclohexyl-H); 13C NMR (100 MHz, CDCl3) d 174.8
(C@O), 145.2, 137.4, 135.1, 134.3, 129.2 (2C), 128.5 (2C), 122.7
(2C), 120.7 (2C) [Ar-C], 46.4, 29.7 (2C), 29.6, 25.6 (2C), 25.5 [aliph.
C]; LC–MS: m/z 360.2 [M+ +1].
4.3.5. 4-(Cyclohexanecarboxamido)phenyl 4-methylbenzene-
sulfonate (1e)
Yield: 88%; mp: 171–4 C; IR (KBr disc, cm1): 3740 (NH), 2927,
2855 (CAH stretching), 1656 (C@O), 1528, 1377 (OSO2); 1H NMR
(400 MHz, CDCl3) d 7.68 (d, 2H, Ar-H, J = 8.0 Hz), 7.45 (d, 2H, Ar-
H, J = 8.0 Hz), 7.30 (d, 2H, Ar-H, J = 8.0 Hz), 7.25 (br s, 1H, NH),
6.90 (d, 2H, Ar-H, J = 8.0 Hz), 2.44 (s, 3H, CH3), 2.20–2.17 (m, 1H,
cyclohexyl-H), 1.92 (d, 2H, cyclohexyl-H, J = 12.0 Hz), 1.85–1.81
(m, 2H, cyclohexyl-H), 1.71–1.68 (m, 1H, cyclohexyl-H), 1.55–
1.46 (m, 2H, cyclohexyl-H), 1.32–1.30 (m, 2H, cyclohexyl-H); 13C
NMR (100 MHz, CDCl3) d 174.4 (C@O), 145.4, 137.0, 132.2, 129.8
(2C), 128.6 (2C), 122.9 (2C), 120.5 (2C) [Ar-C], 46.5, 29.6 (2C),
25.6 (2C), 21.7, 14.1 [aliph. C]; LC–MS: m/z 373.91 [M+ +1].4.3.6. 4-(Cyclohexanecarboxamido)phenyl 4-(tert-butyl)
benzenesulfonate (1f)
Yield: 85%; mp: 174–7 C; IR (KBr disc, cm1): 3369 (NH), 2956,
2922, 2851 (CAH stretching), 1671 (C@O), 1406, 1378 (OSO2); 1H
NMR (400 MHz, CDCl3) d 7.74 (d, 2H, Ar-H, J = 8.0 Hz), 7.52 (d,
2H, NH, J = 4.0 Hz), 7.46 (d, 2H, Ar-H, J = 8.0 Hz), 7.34 (br s, 1H,
NH), 6.92 (d, 2H, Ar-H, J = 8.0 Hz) 2.25–2.17 (m, 1H, cyclohexyl-
H), 1.92 (d, 2H, J = 12.0 Hz), 1.84–1.80 (m, 2H, cyclohexyl-H),
1.70–1.66 (m, 2H, cyclohexyl-H), 1.55–1.46 (m, 2H, cyclohexyl-
H), 1.34 (s, 9H, tert-butyl-9H), 1.27–1.24 (m, 2H, cyclohexyl-H);
13C NMR (100 MHz, CDCl3) d 174.5 (C@O), 145.4, 137.1, 132.2,
128.4 (2C), 126.2 (2C), 122.9 (2C), 120.5 (2C) [Ar-C], 46.5, 29.6
(2C), 25.6 (3C) [aliph. C]. LC–MS: m/z 416.21 [M+ +1].
4.3.7. 4-(Cyclohexanecarboxamido)phenyl 4-fluorobenzene-
sulfonate (1g)
Yield: 87%; mp: 154–5 C; IR (KBr disc, cm1): 3316 (NH), 2929,
2853 (CAH stretching), 1665 (C@O), 1519, 1379 (OSO2); 1H NMR
(400 MHz, CDCl3) d 7.85–7.81(m, 2H, Ar-H), (d, 2H, Ar-H,
J = 8.0 Hz), 7.47 (d, 2H, Ar-H, J = 8.0 Hz), 7.27 (br s, 1H, NH), 7.22–
7.17 (m, 2H), 6.91 (d, 2H, Ar-H, J = 8.0 Hz), 2.44 (s, 3H, CH3),
2.25–2.17 (m, 1H, cyclohexyl-H), 1.93 (d, 2H, cyclohexyl-H,
J = 12.0 Hz), 1.85–1.81 (m, 2H, cyclohexyl-H), 1.71–1.69 (m, 1H,
cyclohexyl-H), 1.57–1.47 (m, 2H, cyclohexyl-H), 1.35–1.21 (m,
3H, cyclohexyl-H); 13C NMR (100 MHz, CDCl3) d 174.5 (C@O),
145.2, 137.2, 131.5 (2C), 131.4, 122.9 (2C), 120.6, 116.7 (2C),
116.5 (2C) [Ar-C], 46.5, 29.6 (2C), 25.6 (3C) [aliph. C]; LC–MS: m/
z 378.23 [M+ +1].
4.3.8. 4-(Cyclohexanecarboxamido)phenyl 4-(trifluoromethyl)
benzenesulfonate (1h)
Yield: 85%; mp: 171–2 C; IR (KBr disc, cm1): 3327 (NH), 2931,
2850 (CAH stretching), 1661 (C@O), 1407, 1386 (OSO2); 1H NMR
(400 MHz, CDCl3) d 7.96 (d, 2H, Ar-H, J = 8.0 Hz), 7.80 (d, 2H, Ar-
H, J = 8.0 Hz), 7.49 (d, 2H, Ar-H, J = 8.0 Hz), 7.36 (br s, 1H, NH),
6.92 (d, 2H, Ar-H, J = 8.0 Hz), 2.25–2.18 (m, 1H, cyclohexyl-H),
1.92 (d, 2H, cyclohexyl-H, J = 12.0 Hz), 1.85–1.81 (m, 2H, cyclo-
hexyl-H), 1.71–1.68 (m, 2H, cyclohexyl-H), 1.56–1.47 (m, 2H,
cyclohexyl-H), 1.31–1.24 (m, 2H, cyclohexyl-H); 13C NMR
(100 MHz, CDCl3) d 174.6 (C@O), 145.0, 138.8, 137.5, 136.0, 129.1
(2C), 126.4 (2C), 126.3, 122.7 (2C), 120.7 (2C) [Ar-C], 46.5, 29.6
(2C), 25.6 (3C) [aliph. C]; LC–MS: m/z 427.94 [M+ +1].
4.3.9. 4-(Cyclopentanecarboxamido)phenyl 4-methylbenzene-
sulfonate (1i)
Yield: 80%; mp: 151–3 C; IR (KBr disc, cm1): 3731 (NH), 2917,
2845 (CAH stretching), 1655 (C@O), 1527, 1375 (OSO2); 1H NMR
(400 MHz, CDCl3) d 7.69 (d, 2H, Ar-H, J = 12.0 Hz), 7.62 (br s, 1H,
NH), 7.47 (d, 2H, Ar-H, J = 8.0 Hz), 7.31 (d, 2H, Ar-H, J = 8.0 Hz),
6.89 (d, 2H, Ar-H, J = 8.0 Hz), 2.71–2.63 (m, 1H, cyclopentyl-H),
2.45 (s, 3H, CH3), 1.92–1.74 (m, 6H, cyclopentyl-H), 1.61–1.57 (m,
2H, cyclopentyl-H); 13C NMR (100 MHz, CDCl3) d 175.0 (C@O),
145.5, 145.2, 137.3, 132.1, 129.8 (2C), 128.5 (2C), 122.8 (2C),
120.5 (2C) [Ar-C], 46.4, 30.5 (2C), 26.0 (2C), 21.7 [aliph. C]; LC–
MS: m/z 359.75 [M+ +1].
4.4. Synthesis of the target sulfamate compounds 1j–m
A solution of compound 4a,b (0.456 mmol) in dry DMF (10 mL)
was cooled to 0 C, and NaH (60% dispersion in mineral oil,
18.2 mg, 0.456 mmol) was added thereto under nitrogen atmo-
sphere. A solution of the appropriate sulfamoyl chloride
(2.0 mmol) in dry DMF (3 mL) was added dropwise to the reaction
mixture at the same temperature. The reaction mixture was stirred
at room temperature overnight. After reaction completion, the
mixture was quenched with ethyl acetate (10 mL) and water
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was extracted with ethyl acetate (3  5 mL). The combined organic
layer extract were washed with saline (3  10 mL), and dried over
anhydrous sodium sulfate. The organic solvent was evaporated
under reduced pressure, and crude residue was purified by column
chromatography (silica gel, appropriate ratio of hexane/ethyl acet-
ate) to obtain the pure product.
4.4.1. 4-(Cyclohexanecarboxamido)phenyl sulfamate (1j)
Yield: 83%; mp: 174–6 C; IR (KBr disc, cm1): 3393 (NH), 3299
(NH2), 2932, 2855 (CAH stretching), 1661 (C@O), 1532, 1374
(OSO2); 1H NMR (400 MHz, CDCl3) d 7.63 (d, 2H, Ar-H,
J = 12.0 Hz), 7.27 (d, 2H, Ar-H, J = 8.0 Hz), 2.42–2.35 (m, 1H,
aliph.-H), 1.92–1.74 (m, 5H, aliph.-H), 1.60–1.50 (m, 2H), 1.41–
1.27 (m, 2H, aliph.-H); 13C NMR (100 MHz, CDCl3) d 176.3 (C@O),
146.5, 137.2, 122.3 (2C), 120.8 (2C) [Ar-C], 45.7, 29.3 (2C), 25.5,
25.4 (2C) [aliph. C]; LC–Ms: m/z 299.08 [M+ +1].
4.4.2. 4-(Cyclohexanecarboxamido)phenyl methylsulfamate
(1k)
Yield: 90%; mp: 162–5 C; IR (KBr disc, cm1): 3364 (NH), 3177
(NH), 2936, 2853 (CAH stretching), 1671 (C@O), 1538, 1340
(OSO2); 1H NMR (400 MHz, CDCl3) d 7.63 (d, 2H, Ar-H, J = 8.0 Hz),
7.25 (d, 2H, Ar-H, J = 8.0 Hz), 2.81 (s, 3H, CH3), 2.42–2.35 (m, 1H,
aliphatic CAH), 1.92–1.84 (m, 4H, aliphatic CAH), 1.77–1.74 (m,
1H, aliphatic CAH), 1.60–1.50 (m, 2H, aliphatic CAH), 1.44–1.28
(m, 3H, aliphatic CAH); 13C NMR (100 MHz, CDCl3) d 176.3
(C@O), 146.2, 137.3, 122.8 (2C), 120.9(2C) [Ar-C], 45.7 (CH3), 29.3
(2C), 28.5, 25.5, 25.4 (2C) [aliph. C]; LC–Ms: m/z 312.99 [M+ +1].
4.4.3. 4-(Cyclohexanecarboxamido)phenyl dimethylsulfamate
(1l)
Yield: 89%; mp: 155–8 C; IR (KBr disc, cm1): 3333 (NH), 2926,
2851 (CAH stretching), 1661 (C@O), 1522, 1365 (OSO2); 1H NMR
(400 MHz, CDCl3) d 8.07 (br s, 1H, NH), 7.56 (d, 2H, Ar-H,
J = 8.0 Hz), 7.17–7.15 (m, 2H, Ar-H), 2.93 (s, 6H, N(CH3)2), 2.29–
2.21 (m, 1H,aliphatic CAH), 1.89 (d, 2H, aliphatic CAH,
J = 8.0 Hz), 1.79 (d, 2H, aliphatic CAH, J = 4.0 Hz), 1.67 (s, 1H,alipha-
tic CAH) 1.52–1.47 (m, 2H,aliphatic CAH), 1.24 (d, 3H,aliphatic
CAH, J = 8.0 Hz); 13C NMR (100 MHz, CDCl3) d 175.1 (C@O),
145.0, 137.2, 122.1 (2C), 121.0 (2C) [Ar-C], 46.2, 38.7, 29.6 (2C),
25.6 (2C), 25.5 (2C) [aliph. C]; LC–Ms: m/z 327.22 [M+ +1].
4.4.4. 4-(Cyclopentanecarboxamido)phenyl methylsulfamate
(1m)
Yield: 89%; mp: 142–4 C; IR (KBr disc, cm1): 3288 (NH), 2925,
2855 (CAH stretching), 1660 (C@O), 1540, 1506 (OSO2); 1H NMR
(400 MHz, CDCl3) d 7.64 (d, 2H, Ar-H, J = 8.0 Hz), 7.25 (d, 2H, Ar-
H, J = 8.0 Hz), 2.81 (s, 3H, CH3), 1.98–1.94 (m, 2H, cyclohexyl-H),
1.87–1.74 (m, 4H, cyclohexyl-H), 1.69–1.65 (m, 2H, cyclohexyl-
H);13C NMR (100 MHz, CDCl3) d 176.4 (C@O), 146.2, 137.3, 122.0
(2C), 120.0 (2C) [Ar-C], 45.8, 30.2 (2C), 28.5, 25.7 (2C) [aliph. C];
LC–MS: m/z 298.95 [M+ +1].
4.5. Biology
STS inhibitory assays were performed as described previously.26
A compound’s ability to inhibit STS activity was determined using
the lysate of JEG-3, a human placenta choriocarcinoma cell line. To
determine STS inhibition, activity was measured in the presence of
the inhibitor (0.5–10 lM) using [3H]E1S (4  105 dpm, Perkin
Elmer) adjusted to 20 lMwith unlabelled E1S substrate. After incu-
bation of the substrate-inhibitor with JEG-3 lysate (125 lg of pro-
tein/mL) for 1 h, the product formed was isolated from the mixture
by extraction with toluene (4 mL), using [4-14C]E1 (American Radi-
olabeled Chemicals) to monitor procedural losses.Intact monolayers of JEG-3 cells were incubated for 20 h at
37 C with [3H]E1S (5 pmol, 7  105 dpm, 60 Ci/mmol) in serum-
free Eagle’s Minimal Essential Medium (1.0 mL) with or without
inhibitors (1011–100 lM). After incubation, medium (0.5 mL)
was removed and product estrone separated from E1S by solvent
partition using toluene (4 mL). [14C]Estrone (7  103 dpm,
52 mCi/mmol) was used to correct for procedural losses. An aliquot
of the organic phase was added to scintillation fluid and the 3H and
14C content measured by scintillation spectrometry. The mass of
E1S hydrolyzed was calculated from the 3H counts detected (cor-
rected for the volume of medium and organic solvent used and
for recovery of 14C counts) and the specific activity of the substrate.
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